Results 231 to 240 of about 180,278 (321)

MHC Class I/Peptide Stability: Implications for Immunodominance, In Vitro Proliferation, and Diversity of Responding CTL [PDF]

, 1998
Dirk H. Busch, Eric G. Pamer
openalex   +1 more source

Genome‐Wide Aggregated Trans Effects Analysis Identifies Genes Encoding Immune Checkpoints as Core Genes for Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective The sparse effector “omnigenic” hypothesis postulates that the polygenic effects of common single nucleotide polymorphisms (SNPs) on a typical complex trait are mediated by trans effects that coalesce on expression of a relatively sparse set of core genes.
Athina Spiliopoulou, Andrii Iakovliev, Darren Plant, Megan Sutcliffe, Seema Sharma, Cankut Cubuk, Myles Lewis, Costantino Pitzalis, Anne Barton, Paul M. McKeigue   +9 more
wiley   +1 more source

Pan-cancer analysis of ITGB3 as a potential prognostic and immunological biomarker. [PDF]

Discov Oncol
Chen C, Wen L, Chen G, Yang F, Chen Z, Ji J, Gu J.   +6 more
europepmc   +1 more source

IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. [PDF]

, 1996
Nina Bhardwaj, R A Seder, A. Reddy, M V Feldman   +3 more
openalex   +1 more source

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease‐modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK‐pot" study)

Arthritis &Rheumatology, Accepted Article.
Objective To assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF‐inhibitors (TNFi) or biologic Disease‐Modifying Anti‐Rheumatic Drugs with other modes of action (bDMARD‐OMA) in a multi‐country, real‐world population.
Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone, Tore K Kvien, Burkhard F Leeb, Dan Nordström, Lucia Otero‐Varela, Karel Pavelka, Manuel Pombo‐Suarez, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Sella A Provan, Anja Strangfeld, Trokovic Nina, Jakub Zavada, Lianne Kearsley‐Fleet, Delphine S Courvoisier, Axel Finckh, Kim Lauper   +28 more
wiley   +1 more source

Integrated multi-omics analysis and machine learning refine molecular subtypes and clinical outcome for hepatocellular carcinoma. [PDF]

Hereditas
Li C, Hu J, Li M, Mao Y, Mao Y.
europepmc   +1 more source

CTL Escape Viral Variants

, 1995
Hanna Lewicki, Antoinette Tishon, Persephone Borrow, Claire F. Evans, Jean Edouard Gairin, Klaus M. Hahn, David A. Jewell, Ian A. Wilson, Michael B. A. Oldstone   +8 more
openalex   +1 more source

Peptide-independent Recognition by Alloreactive Cytotoxic T Lymphocytes (CTL) [PDF]

, 1997
Pam Smith, Anders Brunmark, Michael R. Jackson, Terry A. Potter   +3 more
openalex   +1 more source

Investigation of antibacterial and anticancer activities of biosynthesized metal‐doped and undoped zinc oxide nanoparticles

Biotechnology and Applied Biochemistry, EarlyView.
Abstract Over the past 10 years, nanotechnology has emerged as a very promising technique for a wide range of biomedical applications. Green synthesized metal and metal oxide nanoparticles (NPs) are cheap, easy to produce in large quantities, and safe for the environment.
Kaan Şendal, Mahmure Üstün Özgür, Ebru Ortadoğulu Sucu, Melike Başak Findik, Ömer Erdoğan, Erman Oryaşin, Özge Çevik   +6 more
wiley   +1 more source

A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer. [PDF]

BMC Cancer
Baba K, Suzuki N, Imamura CK, Booka E, Takeuchi M, Takahari D, Kawakami T, Kawakubo H, Kitagawa C, Kono Y, Ogura K, Kito Y, Saito K, Yamamoto S, Takeuchi H, Kudo T, Tsunoda T, Mizukami T, Yamaguchi T, Shoji H, Saito K, Tanoue K, Baba E, Nagashima K, Boku N.   +24 more
europepmc   +1 more source